Why GlaxoSmithKline plc is my FTSE 100 stock pick for the next decade

The FTSE 100 (INDEXFTSE:UKX) is still probably the best index for long-term investors, and GlaxoSmithKline plc (LON: GSK) could be its hottest prospect right now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I reckon all UK stock investment portfolios are best if based on a solid selection of FTSE 100 companies, ideally from several sectors to spread the risk. But I’m occasionally asked which would be my choice if I could only hold one.

In the past I’d have gone for BP or Royal Dutch Shell, bacause energy is never going to go out of fashion and they’ve been dividend cash cows for decades. They’re still great long-term investments, but stubbornly low oil prices knock them off my top spot now.

More recently my favourite has been Lloyds Banking Group, which I’ve held since before the Brexit shock — and though the share price is down, I’m happily taking my growing dividends. But the shambles that Brexit is turning into mean Lloyds could be in for a volatile couple of years.

Today’s favourite

The one that really has been catching my eye lately is GlaxoSmithKline (LSE: GSK). I’ve been following Glaxo for a few years now. That’s ever since earnings growth at the pharmaceuticals giant went into reverse when the firm was hit by the expiry of some key best-selling drugs and by increasing competition from generic alternatives. AstraZeneca suffered similarly and the two have been pursuing a programme of beefing up their drug pipelines.

The corner now seems to have been turned by Glaxo, as the company reported a 35% rise in earnings per share last year. But a slowdown to a forecast of 8% growth this year followed by a 2% shrinkage in 2018 and fears of a dividend cut appear to turned investors away, and the shares have slipped in value to 1,314p.

We’re looking at a forward P/E multiple based on 2017 forecasts of only 12 — and with long-term growth potential, I reckon it deserves a rating in excess of the long-term FTSE 100 average, which stands at around 14.

And Glaxo’s dividend, which has been maintained at 80p per share throughout the downturn, is currently set to yield 6%, which is around twice the FTSE 100 average.

Third quarter

At Q3 time, chief executive Emma Walmsley spoke of “sales growth and improved operating margins,” after new product sales rose by 40% to £1.7bn. I think that’s quite impressive at this stage, after a quarter that saw total sales of £7.8bn, as it’s laying the foundations for profits from the company’s next generation of products.

And we’re seeing a constant stream of development progress, with the company’s new COPD treatment Trelegy Ellipta approved for use in the US and the EU, and its Shingrix shingles vaccine being approved in the US and Canada. A US approval application has also been made for another COPD treatment, mepolizumab, with filings for other markets planned for this year and next.

As for the dividend, I’m optimistic and I see improving cash flow as being able to cover good returns over the long term. But even if there’s a cut, I’d still expect a decent yield to be maintained — and reinvesting the cash should help boost research and growth.

I reckon if you pick Glaxo or AstraZeneca, couple that with BP or Shell, maybe choose a bank if you’re not of a nervous disposition, add a dividend-paying energy firm (National Grid would be my choice) and top it off with an insurer (I hold Aviva), you’d have a very sold core portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft owns shares of Aviva and Lloyds Banking Group. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, BP, Lloyds Banking Group, and Royal Dutch Shell. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »

Dividend Shares

850 shares in this dividend giant could make me £1.1k in passive income

Jon Smith flags up one dividend stock for passive income that has outperformed its sector over the course of the…

Read more »

Investing Articles

Unilever shares are flying! Time to buy at a 21% ‘discount’?

Unilever shares have been racing higher this week after a one-two punch of news from the company. Here’s whether I…

Read more »

artificial intelligence investing algorithms
Market Movers

The Microsoft share price surges after results. Is this the best AI stock to buy?

Jon Smith flags up the jump in the Microsoft share price after the latest results showed strong demand for AI…

Read more »

Google office headquarters
Investing Articles

A dividend announcement sends the Alphabet share price soaring. Here’s what investors need to know

As the Alphabet share price surges on the announcement of a dividend, Stephen Wright outlines what investors should really be…

Read more »

Investing Articles

Turning a £20k ISA into an annual second income of £30k? It’s possible!

This Fool UK writer is exploring how to harness the power of dividend shares and compound returns to build a…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Can I turn £10k into a £1k passive income stream with UK shares?

Everyone talks about the magical 10% mark when it comes to passive income investing, but how realistic is it to…

Read more »

Investing Articles

3 market-beating international investment funds for a Stocks and Shares ISA

It always pays to look for new ways to add extra diversity to a Stocks and Shares ISA. I think…

Read more »